Mediation analyses of the effect of ertugliflozin on hospitalisation for heart failure in patients with type 2 diabetes and atherosclerotic cardiovascular disease from the VERTIS CV trial
Event:
ESC Congress 2021 - The Digital Experience
Topic:
Pharmacotherapy
Session:
Can we improve outcomes by targeting metabolic risk?